TREM2 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 97%.
TREM2_HUMAN, TREM2a, TREM2b, TREM2c, Trggering receptor expressed on myeloid cells 2, Trggering receptor expressed on myeloid cells 2a, Triggering receptor expressed on monocytes 2, Triggering receptor expressed on myeloid cells 2
TREM2 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 97%.
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of 4x105 cells/mL. Seeding density is given as a guide only and should be scaled to align with individual lab schedules.
4. Incubate the culture at 37°C incubator with 5% CO2. Cultures should be monitored daily.
5. THP-1 cells recover slowly from cryopreservation and therefore may not be ready for subculture for a number of days. Cells should be left as much as possible over this time and only subcultured when the cell density reaches 8x105 cells/mL.Small amounts of fresh media can be added until cell number/viability improves.
Recommended control: Human wild-type THP-1 cell line (ab271147). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
TREM2 also known as Triggering Receptor Expressed on Myeloid Cells 2 functions as a receptor with an important role in the immune system. This protein weighing about 230-290 kDa mostly expresses in myeloid cells which include macrophages monocytes and microglia. It serves as an important player in signaling for the activation of these cells. Researchers often study TREM2's functions through various species including cynomolgus monkeys to understand its implications better.
TREM2 significantly influences immune responses by participating in cellular clearance functions such as phagocytosis. It forms a receptor complex with DAP12 which transduces signals leading to the activation of immune responses. TREM2 aids in regulating inflammatory responses and ensures the maintenance of tissue homeostasis in healthy and diseased states. Its role extends to the control of lipid metabolism particularly in the central nervous system.
Scientific studies link TREM2 to the immune-inflammatory pathway and the neurodegenerative pathway. Within these pathways TREM2 interacts notably with proteins such as DAP12 and SYK. Through these interactions TREM2 contributes to signaling cascades that modulate inflammation and neurodegenerative processes within the brain supporting cellular communication and survival.
TREM2's functionality connects significantly with Alzheimer's disease and various inflammatory conditions. In Alzheimer's disease mutations in TREM2 alter its normal activity potentially increasing neuroinflammation and advancing disease progression. Additionally collaborations between TREM2 and ApoE proteins further highlight its involvement in lipid regulation within neurodegenerative conditions. Understanding TREM2’s role can pave the way for targeted therapeutic approaches in these disorders.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Anti-TREM2 antibody [EPR20243] ab209814 was shown to react with TREM2 in wild-type THP-1 cells in Western blot with loss of signal observed in TREM2 knockout cell line ab269489 (TREM2 knockout cell lysate Human TREM2 knockout THP-1 cell lysate ab269652). Wild-type THP-1 and TREM2 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with Anti-TREM2 antibody [EPR20243] ab209814 and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes: Western blot - Anti-TREM2 antibody [EPR20243] (Anti-TREM2 antibody [EPR20243] ab209814) at 1/1000 dilution
Lane 1: Wild-type THP-1 cell lysate at 20 µg
Lane 2: TREM2 knockout THP-1 cell lysate at 20 µg
Lane 2: Western blot - Human TREM2 knockout THP-1 cell line (ab269489)
Lane 3: HL-60 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 25 kDa
Observed band size: 30 kDa
Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 97%
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com